diphenidol

Trade name: vontrol

Small moleculeapproved

Approved

Apr 5, 1967

Diphenidol, a nonphenothiazinic antiemetic agent used primarily in patients with Meniere disease and labyrinthopathies to treat vomiting and vertigo, is considered to be a relatively safe drug. Since it was first approved in the United States in 1967, this drug has been widely used in Latin America and Asia and has contributed to sporadic suicidal and accidental poisonings in mainland China and Taiwan. The mechanism by which diphenidol exerts its antiemetic and antivertigo effects is not precisely known. It is thought to diminish vestibular stimulation and depress labyrinthine function and as an antimuscarinic agent. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Diphenidol has no significant sedative, tranquilizing, or antihistaminic action. It has a weak peripheral anticholinergic effect. Diphenidol is used to relieve or prevent nausea, vomiting, and dizziness caused by certain medical problems. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Apr 1, 2010 (NCT01574313)

Timeline

1960s

Apr 5, 1967
GlaxoSmithKline — Earliest FDA Approval
Apr 5, 1967
GlaxoSmithKline — Marketing Organization
Apr 5, 1967
GlaxoSmithKline — NDA Organization

Indications

Approved for

Vertigo (approved 1967)

Studied for

Mechanism of action

Muscarinic acetylcholine receptor M1ANTAGONIST
CHRM1 antagonist
antiemetic
- Muscarinic acetylcholine receptor M1 (CHRM1) ↗

Approval history

approvedApr 5, 1967

Chemistry & pharmacology

Loading structure…

SMILES

OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1

Mol. weight: 309.45 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Discontinued

Oral

Yes

Parenteral

Topical

Sources

Also known as

alpha,alpha-diphenyl-1-piperidinebutanol
alpha,alpha-diphenyl-1-piperidinebutanol
alpha,alpha-diphenyl-1-piperidinebutanol
benproperine
benproperine
benproperine
benproperine
benproperine
cefadol
cephadol
cephadol
cryopharma brand of diphenidol hydrochloride
difenidol
difenidol
difenidol
difenidol
difenidol
difenidol embonate
difenidol hcl
difenidol hcl
difenidol hcl
difenidol hydrochloride
difenidolo
difenidolo
difenidolum
difenidolum
diphenadol
diphenidol
diphenidol
diphenidol
diphenidol
diphenidol
diphenidol
diphenidol
diphenidol
diphenidol
diphenidol
diphenidol hcl
diphenidol hcl
diphenidol hcl
diphenidol hydrochloride
diphenidol hydrochloride
diphenidol hydrochloride
diphenidol hydrochloride
diphenidol hydrochloride
diphenidol hydrochloride, alpha-(14)c-labeled
diphenidol pamoate
diphenyl(3-(1-piperidyl)propyl)carbinol
diphenyl(3-(1-piperidyl)propyl)carbinol
glaxosmithkline brand of diphenidol hydrochloride
lansenol
normavom
sk-478
sk-478
sk-478-a
sk-478-a
sk&f-478
sk&f-478
sk&f-478a
sk&f-478a
smithkline beecham brand of diphenidol hydrochloride
vontrol
vontrol
vontrol
vontrol

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01574313	Phase 4	Apr 1, 2010	Chimei Medical Center

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Chimei Medical Center	Academic/Hospital	1	1	1	2010

1 organizations

Page 1 / 1

Marketing (2)

Organization	Org type	Relationship	Date
GlaxoSmithKline	For profit	MKTG	Apr 5, 1967
GlaxoSmithKline	For profit	NDA	Apr 5, 1967